Innospec (Nasdaq: IOSP) reported earnings on May 6. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Innospec missed estimates on revenues and whiffed on earnings per share.

Compared to the prior-year quarter, revenue shrank slightly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.

Margins dropped across the board.

Revenue details
 Innospec chalked up revenue of $199.4 million. The three analysts polled by S&P Capital IQ anticipated net sales of $205.6 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.72. The five earnings estimates compiled by S&P Capital IQ averaged $0.87 per share. Non-GAAP EPS of $0.72 for Q1 were 28% lower than the prior-year quarter's $1.00 per share. GAAP EPS of $0.75 for Q1 were 27% lower than the prior-year quarter's $1.03 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 32.0%, 20 basis points worse than the prior-year quarter. Operating margin was 11.3%, 470 basis points worse than the prior-year quarter. Net margin was 9.0%, 330 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $187.8 million. On the bottom line, the average EPS estimate is $0.77.

Next year's average estimate for revenue is $823.3 million. The average EPS estimate is $3.59.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 71 members out of 80 rating the stock outperform, and nine members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Innospec a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Innospec is buy, with an average price target of $46.00.

Looking for alternatives to Innospec? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.